New Rebif (Interferon Beta-1a) Initiation Pack For Patients With Relapsing Remitting Multiple Sclerosis
Medical News Today Tue, 26 Jun 2007 1:09 AM PDT
Merck Serono has announced the launch of a new Rebif initiation pack for patients with relapsing remitting multiple sclerosis (RRMS). It is important when patients begin interferon beta therapy that the dose is gradually increased over a four week period as this helps minimise possible side effects. [click link for full article]

UCB and Biogen Idec's Oral VLA-4 Antagonist (CDP323) Enters Phase II Development for Multiple Sclerosis
RedNova Tue, 26 Jun 2007 1:07 AM PDT
Brussels (Belgium) and Cambridge, MA (USA) - June 26, 2007- 7:00 am CET - UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) today announced the initiation of a Phase II study of CDP323 - an oral VLA-4 antagonist - under development for relapsing-remitting multiple sclerosis (MS).

Clinical Trials Update: June 25, 2007
HealthDay via Yahoo! News Mon, 25 Jun 2007 11:02 AM PDT
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

MediciNova Announces New Strategic Initiative
RedNova Tue, 26 Jun 2007 6:26 AM PDT
SAN DIEGO, June 26, 2007 (PRIME NEWSWIRE) -- Me

Genzyme Stock Rises on Lehman Upgrade
Houston Chronicle - United States
... toxins that can damage the large intestine. Other positive pipeline opportunities include the leukemia drug Campath as a treatment for multiple sclerosis.
See all stories on this topic

Genmab to get 116.3 mln dkr from GSK in first milestone payment ...
Hemscott - London,UK
Genmab licensed exclusive worldwide rights to co-develop and commercialise ofatumumab to GSK in December 2006. michael.delaine@thomson.com mdl/am.
See all stories on this topic

Market Report -- In Play (MNOV)
MSN Money - USA
... of market opportunities, it will focus its resources on development and commercialization of two assets in its development pipeline, MN-221 and MN-166. ...
See all stories on this topic

MediciNova Announces New Strategic Initiative
CNNMoney.com - USA
MN-166, an oral treatment for multiple sclerosis, demonstrated positive clinical benefits and a superior safety profile after one year of treatment in a ...
See all stories on this topic

Ahead of the Bell: Biogen Idec
Houston Chronicle - United States
The analyst is also concerned the company does not have enough promising drug candidates, suggesting its multiple sclerosis drug Tysabri may not be approved ...
See all stories on this topic

Commercial Insight: Multiple Sclerosis Continued growth makes the ...
Pharmaceutical Business Review - USA
Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch ...
See all stories on this topic

Biogen Idec Inc. (BIIB) Holds Near Recent Peak
Schaeffers Research - Cincinnati,OH,USA
In a post last month, I discussed that zone and the issues surrounding Tysabri. I ended that post saying the chart seemed mildly constructive and the action ...
See all stories on this topic

Genzyme Stock Rises on Lehman Upgrade
Houston Chronicle - United States
... toxins that can damage the large intestine. Other positive pipeline opportunities include the leukemia drug Campath as a treatment for multiple sclerosis.
See all stories on this topic